close

Agreements

1 239 240 241 242 243 257
Number of results: 5132

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-11-30 Q Chip (UK) undisclosed leading international speciality pharmaceutical company sustained release depot of an undisclosed therapeutic peptide

development

Development agreement
2011-11-30 Vitamfero (France) Oniris (France) vaccine candidate against bovine (cattle) neosporosis neosporosis

collaboration
services

Veterinary medicine Services contract
2011-11-28 Bavarian Nordic (Denmark) US Government (USA) Imvamune® smallpox vaccine smallpox development Infectious diseases Development agreement
2011-11-23 Proximagen (UK) Altacor (UK) PRX00933, the lead compound from Proximagen’s 5HT2c programme glaucoma

R&D

Ophtalmological diseases R&D agreement
2011-11-22 OctoPlus (The Netherlands) undisclosed partner Additional drug product

undisclosed

Manufacturing
Production
2011-11-18 Shire (UK) Shionogi (Japan) certain of Shire’s Attention Deficit Hyperactivity Disorder (ADHD) medicines Attention deficit hyperactivity disorder (ADHD)

development
commercialisation

Mental diseases - Psychiatric diseases Development agreement
2011-11-17 Cenix BioScience (Germany) SYGNIS Bioscience (Germany)

R&D

CNS diseases R&D agreement
2011-11-16 Genzyme (USA - MA), a Sanofi company (France) Cystic Fibrosis Foundation Therapeutics (USA) new cystic fibrosis drugs cystic fibrosis research - R&D Rare diseases - Genetic diseases R&D agreement
2011-11-15 UCB (Belgium) Parexel (USA) PRA (USA) clinical development services

clinical development

Services contract
2011-11-15 Almirall (Spain) Biofocus, a Galapagos Company (UK - Belgium) new hit compounds against key targets of interest to Almirall respiratory and inflammatory conditions

R&D

Respiratory diseases - Inflammatory diseases R&D agreement
2011-11-09 Ablynx (Belgium) Merck Serono (Germany) Nanobodies® against two targets in osteoarthritis osteoarthritis

R&D

Rheumatic diseases - Inflammatory diseases – Bone diseases R&D agreement
2011-11-09 Dako (Denmark) BMS (USA) pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb

development

 

Development agreement
2011-11-08 ADx NeuroSciences (Belgium) KU Leuven (Belgium) antibodies used in dementia diagnosis

development
licensing

 

 

Neurodegenerative diseases Development agreement
2011-11-07 Antitope (UK) Therapure Biopharma (Canada) therapeutic monoclonal antibodies

R&D

R&D agreement
2011-11-07 Oxford Gene Technology (UK) Abcodia (UK) pancreatic cancer specific biomarkers pancreatic cancer

development
collaboration

Cancer - Oncology Development agreement
2011-11-03 Ark Therapeutics (UK) University of Glasgow's Institute of Cardiovascular and Medical Sciences (UK) adenoviral vector expressing TIMP3 gene vein graft failure associated with coronary artery bypass surgery

manufacturing
production

Cardiovascular diseases Production agreement
2011-11-02 MorphoSys (Germany) Shionogi (Japan) HuCAL antibody technology and additional proprietary technology modules for research in drug discovery

R&D

licensing

R&D agreement
2011-11-02 Exonhit (France) Allergan (USA) new drugs for the treatment of neurodegenerative diseases, pain and ophthalmology

R&D

development

commercialisation

Neurodegenerative diseases - Ophtalmological diseases - CNS diseases R&D agreement
2011-11-02 Illumina (USA) Siemens Healthcare Diagnostics (USA), subsidiary of Siemens AG (Germany) next-generation sequencing for the rapid, accurate identification of patients\' infectious disease states and potential treatment paths.

development

Infectious diseases Development agreement
2011-11-02 BioQuanta (France) Gentronix (UK) Mitoxis® functional metabolomics platform

distribution
commercialisation

Commercialisation agreement